Clinical Trial Update: A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy [Phase 3]

View source ↗

Summary

Phase 3 trial update reporting long-term safety and efficacy results for VX-445 combination therapy in cystic fibrosis; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• VX-445 Combination Therapy (elexacaftor/tezacaftor/ivacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 3 | Status: COMPLETED | Results posted: 2024-05-08